THE INTESTINALLY RESTRICTED, ORALLY ADMINISTERED, PAN-JAK INHIBITOR TD-1473 DEMONSTRATES FAVORABLE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND SIGNAL FOR CLINICAL ACTIVITY IN SUBJECTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

William Sandborn  1     Raj Bhandari  2     Jonathan A. Leighton  3     Ravi Ganeshappa  4     Deanna Nguyen  5     Brian Ferslew  5     Ann Olmsted  6     Richard Graham     Julian PanĂ©s    
1 University of California San Diego,San Diego,United States
2 Delta Research Partners,Monroe,United States
3 Mayo Clinic Phoenix,Phoenix,United States
4 Pinnacle Clinical Research,San Antonio,United States
5 Theravance Biopharma,South San Francisco,United States
6 Theravance Biopharma

Conference
UEG Week 2018

Citation
United European Gastroenterology Journal 2018; 6 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing